Observational study of 174 hospitalized patients in Turkey, median age 45.4, 23 treated with HCQ, 113 with HCQ+AZ, and 32 with regimens including favipiravir. 75% reduction in the median time to clinical improvement for HCQ+AZ vs. FAV, RR 0.25, p
<0.001. 83% reduction for HCQ. However, there was significant confounding by indication
There were no significant adverse events.
BaŞaran et al., 28 Jul 2020, prospective, Turkey, peer-reviewed, 18 authors.